Russia's ChemRar gets rights to Pfizer's DPP-IVi diabetes candidate
05:16 EDT 6 Jul 2012 | thePharmaLetter
Russia's ChemRar Hi-Tech Centre, a pharmaceutical investment and R&D group, said yesterday that global drugs behemoth Pfizer (NYSE: PFE) has granted exclusive development and marketing rights to SatRx for its DPP(1)-IVi compound, PF-00734200.
Original Article: Russia's ChemRar gets rights to Pfizer's DPP-IVi diabetes candidate
More From BioPortfolio on "Russia's ChemRar gets rights to Pfizer's DPP-IVi diabetes candidate"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
